These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30915079)

  • 21. Seminal vesicle fluid increases the efficacy of intravaginal HSV-2 vaccination.
    Varese A; Remes Lenicov F; Gonzalez Prinz M; Paletta A; Ernst G; Maeto C; Merlotti A; Sabatte J; Símula S; Holgado MP; Dantas E; Geffner J; Ceballos A
    Mucosal Immunol; 2018 Mar; 11(2):536-548. PubMed ID: 28745327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure.
    Parsons MS; Kristensen AB; Selva KJ; Lee WS; Amarasena T; Esterbauer R; Wheatley AK; Bavinton BR; Kelleher AD; Grulich AE; Khoury G; Juno JA; Kent SJ
    EBioMedicine; 2021 Aug; 70():103518. PubMed ID: 34385004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.
    Burgers WA; Chege GK; Müller TL; van Harmelen JH; Khoury G; Shephard EG; Gray CM; Williamson C; Williamson AL
    J Gen Virol; 2009 Feb; 90(Pt 2):468-480. PubMed ID: 19141458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human male genital tract secretions: both mucosal and systemic immune compartments contribute to the humoral immunity.
    Moldoveanu Z; Huang WQ; Kulhavy R; Pate MS; Mestecky J
    J Immunol; 2005 Sep; 175(6):4127-36. PubMed ID: 16148163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
    Chea LS; Amara RR
    Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form.
    Pattani A; McKay PF; Curran RM; McCaffrey J; Gupta PN; Lowry D; Kett VL; Shattock RJ; McCarthy HO; Malcolm RK
    Vaccine; 2012 Apr; 30(17):2778-85. PubMed ID: 22361120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV infection of the genital mucosa in women.
    Hladik F; Hope TJ
    Curr HIV/AIDS Rep; 2009 Feb; 6(1):20-8. PubMed ID: 19149993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.
    Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.
    Olesen R; Swanson MD; Kovarova M; Nochi T; Chateau M; Honeycutt JB; Long JM; Denton PW; Hudgens MG; Richardson A; Tolstrup M; Østergaard L; Wahl A; Garcia JV
    J Clin Invest; 2016 Mar; 126(3):892-904. PubMed ID: 26854925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the Influence of Semen-Derived Enhancer of Virus Infection on the Interaction of HIV-1 with Female Reproductive Tract Tissues.
    Allen SA; Carias AM; Anderson MR; Okocha EA; Benning L; McRaven MD; Kelley ZL; Lurain J; Veazey RS; Hope TJ
    J Virol; 2015 May; 89(10):5569-80. PubMed ID: 25740984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.
    Kaul R; Plummer FA; Kimani J; Dong T; Kiama P; Rostron T; Njagi E; MacDonald KS; Bwayo JJ; McMichael AJ; Rowland-Jones SL
    J Immunol; 2000 Feb; 164(3):1602-11. PubMed ID: 10640781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV.
    Yeaman GR; White HD; Howell A; Prabhala R; Wira CR
    AIDS Res Hum Retroviruses; 1998 Apr; 14 Suppl 1():S57-62. PubMed ID: 9581885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface.
    Shacklett BL; Cu-Uvin S; Beadle TJ; Pace CA; Fast NM; Donahue SM; Caliendo AM; Flanigan TP; Carpenter CC; Nixon DF
    AIDS; 2000 Sep; 14(13):1911-5. PubMed ID: 10997394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
    Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
    J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract.
    Rebbapragada A; Wachihi C; Pettengell C; Sunderji S; Huibner S; Jaoko W; Ball B; Fowke K; Mazzulli T; Plummer FA; Kaul R
    AIDS; 2007 Mar; 21(5):589-98. PubMed ID: 17314521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.